Alzheimer’s disease(AD)is the main cause of dementia,with its diagnosis and management remaining challenging.Amyloid positron emission tomography(PET)has become increasingly important in medical practice for patients...Alzheimer’s disease(AD)is the main cause of dementia,with its diagnosis and management remaining challenging.Amyloid positron emission tomography(PET)has become increasingly important in medical practice for patients with AD.To integrate and update previous guidelines in the field,a task group of experts of several disciplines from multiple countries was assembled,and they revised and approved the content related to the application of amyloid PET in the medical settings of cognitively impaired individuals,focusing on clinical scenarios,patient preparation,administered activities,as well as image acquisition,processing,interpretation and reporting.In addition,expert opinions,practices,and protocols of prominent research institutions performing research on amyloid PET of dementia are integrated.With the increasing availability of amyloid PET imaging,a complete and standard pipeline for the entire examination process is essential for clinical practice.This international consensus and practice guideline will help to promote proper clinical use of amyloid PET imaging in patients with AD.展开更多
基金This study was partially sponsored by the National Natural Science Foundation of China(NSFC)(81761148029,81725009,82030049,82021002,81971641)Ministry of Science and Technology of China(MOST)(2021YFA110004500,2021YFE0108300)+3 种基金Clinical Research Plan of SHDC(SHDC2020CR1038B)Science and Technology Innovation 2030 Major Projects(2022ZD0211600)Swiss National Science Foundation(project nos.185028,188355,and 169876)National Research Foundation of Korea(NRF-2017K2A9A2A10013554).
文摘Alzheimer’s disease(AD)is the main cause of dementia,with its diagnosis and management remaining challenging.Amyloid positron emission tomography(PET)has become increasingly important in medical practice for patients with AD.To integrate and update previous guidelines in the field,a task group of experts of several disciplines from multiple countries was assembled,and they revised and approved the content related to the application of amyloid PET in the medical settings of cognitively impaired individuals,focusing on clinical scenarios,patient preparation,administered activities,as well as image acquisition,processing,interpretation and reporting.In addition,expert opinions,practices,and protocols of prominent research institutions performing research on amyloid PET of dementia are integrated.With the increasing availability of amyloid PET imaging,a complete and standard pipeline for the entire examination process is essential for clinical practice.This international consensus and practice guideline will help to promote proper clinical use of amyloid PET imaging in patients with AD.
